L A S Van Kerkhoven1, R J F Laheij, J B M J Jansen. 1. Department of Gastroenterology and Hepatology, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands. l.vankerkhoven@mdl.umcn.nl
Abstract
BACKGROUND: Serotonin is associated with symptoms of the irritable bowel syndrome, its action is terminated by the serotonin transporter protein. AIM: To assess the association between a functional polymorphism in the gene encoding for activity of the serotonin transporter protein and the irritable bowel syndrome. METHODS: Meta-analysis of studies identified through a Medline, PubMed and Web of Science search, describing the prevalence of a polymorphism in the serotonin transporter gene creating long and short alleles. RESULTS: Eight eligible studies described a total of 1034 patients with the irritable bowel syndrome, and 1377 healthy controls. Presence of the short allele is not associated with an increased risk for the irritable bowel syndrome: OR 1.0; 95% CI: 0.7-1.4 for homozygous subjects, and OR 1.0; 95% CI: 0.8-1.2 for homozygous subjects and heterozygotes together. Although Caucasians and Asians had diverging genotypic frequencies, no association with the shot allele and irritable bowel syndrome was observed in subgroups: Asians OR 1.2; 95% CI: 0.9-1.6 and OR 1.1; 95% CI: 0.2-5.9; Caucasians OR 0.9; 95% CI: 0.5-1.7 and OR 0.9; 95% CI: 0.7-1.2, respectively, for homozygous subjects alone and for homozygous subjects and heterozygotes together. CONCLUSION: A genetic polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel.
BACKGROUND:Serotonin is associated with symptoms of the irritable bowel syndrome, its action is terminated by the serotonin transporter protein. AIM: To assess the association between a functional polymorphism in the gene encoding for activity of the serotonin transporter protein and the irritable bowel syndrome. METHODS: Meta-analysis of studies identified through a Medline, PubMed and Web of Science search, describing the prevalence of a polymorphism in the serotonin transporter gene creating long and short alleles. RESULTS: Eight eligible studies described a total of 1034 patients with the irritable bowel syndrome, and 1377 healthy controls. Presence of the short allele is not associated with an increased risk for the irritable bowel syndrome: OR 1.0; 95% CI: 0.7-1.4 for homozygous subjects, and OR 1.0; 95% CI: 0.8-1.2 for homozygous subjects and heterozygotes together. Although Caucasians and Asians had diverging genotypic frequencies, no association with the shot allele and irritable bowel syndrome was observed in subgroups: Asians OR 1.2; 95% CI: 0.9-1.6 and OR 1.1; 95% CI: 0.2-5.9; Caucasians OR 0.9; 95% CI: 0.5-1.7 and OR 0.9; 95% CI: 0.7-1.2, respectively, for homozygous subjects alone and for homozygous subjects and heterozygotes together. CONCLUSION: A genetic polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel.
Authors: Yuri A Saito; Gloria M Petersen; Joseph J Larson; Elizabeth J Atkinson; Brooke L Fridley; Mariza de Andrade; G Richard Locke; Janice M Zimmerman; Ann E Almazar-Elder; Nicholas J Talley Journal: Am J Gastroenterol Date: 2010-03-16 Impact factor: 10.864
Authors: Mark W Logue; Sarah R Bauver; William S Kremen; Carol E Franz; Seth A Eisen; Ming T Tsuang; Michael D Grant; Michael J Lyons Journal: Twin Res Hum Genet Date: 2011-02 Impact factor: 1.587
Authors: Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland Journal: Neuropharmacology Date: 2008-09-11 Impact factor: 5.250